Citius Pharmaceuticals Stock

Citius Pharmaceuticals Dividend 2024

Citius Pharmaceuticals Dividend

0 USD

Citius Pharmaceuticals Dividend yield

Ticker

CTXR

ISIN

US17322U2078

WKN

A2DXS0

How much dividend does Citius Pharmaceuticals 2024 pay?

According to the latest status from December 2024, Citius Pharmaceuticals paid a total of 0 USD per share in dividends within the last 12 months. With the current Citius Pharmaceuticals price of 2.59 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Citius Pharmaceuticals Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Citius Pharmaceuticals Dividend Safe?

Citius Pharmaceuticals has been increasing the dividend for 0 years.

Over the past 10 years, Citius Pharmaceuticals has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Citius Pharmaceuticals's Dividend Distributions

Citius Pharmaceuticals’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Citius Pharmaceuticals's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Citius Pharmaceuticals's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Citius Pharmaceuticals’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Citius Pharmaceuticals Aktienanalyse

What does Citius Pharmaceuticals do?

Citius Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for unmet medical needs. The company was founded in 2006 and is headquartered in Cranford, New Jersey. Business Model Citius Pharmaceuticals' business model is based on the development of drugs and therapies for rare and unmet medical needs. The company utilizes its industry experience and knowledge to identify unmet medical needs and develop novel therapeutic approaches. Citius Pharmaceuticals collaborates closely with leading academic and scientific institutions to expedite and enhance the effectiveness of its development projects. History Citius Pharmaceuticals was founded by Myron Holubiak, who has over 30 years of experience in the pharmaceutical and biotech industry. Holubiak previously led drug development efforts for companies such as 3M Pharmaceuticals and Elan Pharmaceuticals. In 2007, Citius Pharmaceuticals went public to raise capital for its development projects. Products and Divisions Citius Pharmaceuticals operates in two main divisions: the first focuses on the development of drugs for rare and unmet medical needs, while the second concentrates on the development of therapies for common conditions such as hemorrhoids and cold sores. One of Citius Pharmaceuticals' products is Mino-Lok®, a medication for the treatment of severe intravenous catheter infections. This product is designed to reduce the need for antibiotics commonly used in such infections. Mino-Lok® is currently in Phase III clinical development. Another product by Citius Pharmaceuticals is Halo-Lido, a new therapy for hemorrhoids. It contains lidocaine and hydrocortisone acetate, and is developed to reduce pain and inflammation associated with hemorrhoids. Halo-Lido has already been approved by the US Food and Drug Administration (FDA) and is currently available on the market. Additionally, Citius Pharmaceuticals has a portfolio of patented and trademarked products that provide a platform for future growth. The company is also working on the development of new therapies for cold sores and other viral infections. Conclusion Citius Pharmaceuticals Inc. is an innovative biopharmaceutical company that identifies the needs of unmet medical areas and develops innovative solutions for treating these conditions. With an experienced management team and a strong portfolio of patented products, Citius Pharmaceuticals is well positioned to continue growing and increasing value for its stakeholders. Citius Pharmaceuticals is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Citius Pharmaceuticals stock

How much dividend does Citius Pharmaceuticals pay?

Over the past 12 months, Citius Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Citius Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Citius Pharmaceuticals?

The current dividend yield of Citius Pharmaceuticals is .

When does Citius Pharmaceuticals pay dividends?

Citius Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Citius Pharmaceuticals?

Citius Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Citius Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Citius Pharmaceuticals located?

Citius Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Citius Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Citius Pharmaceuticals from 12/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/19/2024.

When did Citius Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/19/2024.

What was the dividend of Citius Pharmaceuticals in the year 2023?

In the year 2023, Citius Pharmaceuticals distributed 0 USD as dividends.

In which currency does Citius Pharmaceuticals pay out the dividend?

The dividends of Citius Pharmaceuticals are distributed in USD.

Andere Kennzahlen von Citius Pharmaceuticals

Our stock analysis for Citius Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Citius Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.